The monthly-TPE-alone finding is the secondary positive result of the Aging Cell trial. The 1.32-year reduction (FDR=2.42e-02) is statistically significant within the trial framework. The healthspan extension claim is broader and is not directly supported by the trial data, which measured surrogate molecular endpoints over approximately three months rather than functional or clinical outcomes over years. The verification status is unreplicated for the same reasons that apply to the primary TPE-IVIG finding: single trial, a disclosed conflict of interest (the investigators are members of the commercializing company Circulate, Inc.; the paper states it received no specific funding), surrogate endpoints, no independent replication. The differential between TPE-IVIG (-2.61 years) and monthly TPE alone (-1.32 years) is a methodologically interesting result that distinguishes the protocol from comparators within the trial; the absolute claim that monthly TPE extends healthspan is not yet supported by hard-endpoint data.